Impact of study design on the evaluation of inhaled and intranasal corticosteroids' effect on Hypothalamic-Pituitary-Adrenal Axis Function, Part I: General overview of HPA Axis study design

Journal of Pharmaceutical Sciences

Volumn 102, Issue 10, 2013, Pages 3513-3527

  Fan, Ying ^a   Ma, Lian ^b   Pippins, Jennifer ^a   Limb, Susan ^a   Xu, Yun ^a   Sahajwalla, Chandrahas G ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

Hypothalamic pituitary adrenal axis; Inhaled corticosteroids; Intranasal corticosteroids; Pharmacodynamics; Pulmonary; Regulatory science; Study design

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; HYDROCORTISONE; MOMETASONE FUROATE; PLACEBO; TRIAMCINOLONE ACETONIDE;

ADRENAL SUPPRESSION; ARTICLE; ASTHMA; CORTICOTROPIN TEST; DRUG EFFECT; DRUG SCREENING; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; SYSTEMATIC REVIEW;

HYPOTHALAMIC-PITUITARY-ADRENAL AXIS; INHALED CORTICOSTEROIDS; INTRANASAL CORTICOSTEROIDS; PHARMACODYNAMICS; PULMONARY; REGULATORY SCIENCE; STUDY DESIGN;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; ADRENAL CORTEX HORMONES; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; RESEARCH DESIGN;

EID: 84883775672     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23689     Document Type: Review

References (107)

1. Murray BE, Mathewson JJ, DuPont HL, Ericsson CD, Reves RR. 1990. Emergence of resistant fecal Escherichia coli in travelers not taking prophylactic antimicrobial agents. Antimicrob Agents Chemother 34(4):515-518.
2. 2007. Expert panel report 3 (EPR-3): Guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 120(5 Suppl):S94-S138.
3. Georgitis JW. 1999. The 1997 asthma management guidelines and therapeutic issues relating to the treatment of asthma. National Heart, Lung, and Blood Institute. Chest 115(1):210-217.
4. 2011. GINA report, global strategy for asthma management and prevention. Accessed December, 2011, at: http://www.ginasthma.org: Global Initiative for Asthma (GINA).
5. Newacheck PW, Stoddard JJ. 1994. Prevalence and impact of multiple childhood chronic illnesses. J Pediatr 124(1):40-48.
6. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, Agache I, Ait-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, van Wijk RG, Kalayci O, Kaliner MA, Kim YY, Kowalski ML, Kuna P, Le LT, Lemiere C, Li J, Lockey RF, Mavale-Manuel S, Meltzer EO, Mohammad Y, Mullol J, Naclerio R, O'Hehir RE, Ohta K, Ouedraogo S, Palkonen S, Papadopoulos N, Passalacqua G, Pawankar R, Popov TA, Rabe KF, Rosado-Pinto J, Scadding GK, Simons FE, Toskala E, Valovirta E, van Cauwenberge P, Wang DY, Wickman M, Yawn BP, Yorgancioglu A, Yusuf OM, Zar H, Annesi-Maesano I, Bateman ED, Ben Kheder A, Boakye DA, Bouchard J, Burney P, Busse WW, Chan-Yeung M, Chavannes NH, Chuchalin A, Dolen WK, Emuzyte R, Grouse L, Humbert M, Jackson C, Johnston SL, Keith PK, Kemp JP, Klossek JM, Larenas-Linnemann D, Lipworth B, Malo JL, Marshall GD, Naspitz C, Nekam K, Niggemann B, Nizankowska-Mogilnicka E, Okamoto Y, Orru MP, Potter P, Price D, Stoloff SW, Vandenplas O, Viegi G, Williams D. 2008. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 63 Suppl 86:8-160.
7. Mygind N. 1993. Glucocorticosteroids and rhinitis. Allergy 48(7):476-490.
8. Yanez A, Rodrigo GJ. 2002. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: A systematic review with meta-analysis. Ann Allergy Asthma Immunol 89(5):479-484.
9. Weiner JM, Abramson MJ, Puy RM. 1998. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: Systematic review of randomised controlled trials. BMJ 317(7173):1624-1629.
10. Lipworth BJ, Jackson CM. 2000. Safety of inhaled and intranasal corticosteroids: Lessons for the new millennium. Drug Saf 23(1):11-33.
11. Chrousos GP, Gold PW. 1992. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 267(9):1244-1252.
12. Chrousos GP. 1992. Regulation and dysregulation of the hypothalamic-pituitary-adrenal axis. The corticotropin-releasing hormone perspective. Endocrinol Metab Clin North Am 21(4):833-858.
13. Harney, JW. 1995. The adrenal cortex. In Clinical pediatric endocrinology; Charle G.D. Brook, Ed. Oxford, England: Blackwell Scientific Publications, pp 434-452.
14. Adinoff B, Iranmanesh A, Veldhuis J, Fisher L. 1998. Disturbances of the stress response: The role of the HPA axis during alcohol withdrawal and abstinence. Alcohol Health Res World 22(1):67-72.
15. Lipworth BJ. 1999. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 159(9):941-955.
16. Lipworth BJ, Seckl JR. 1997. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 52(5):476-482.
17. Brown PH, Blundell G, Greening AP, Crompton GK. 1992. High dose inhaled steroid therapy and the cortisol stress response to acute severe asthma. Respir Med 86(6):495-497.
18. Kehlet H, Binder C. 1973. Adrenocortical function and clinical course during and after surgery in unsupplemented glucocorticoid-treated patients. Br J Anaesth 45(10):1043-1048.
19. Meibohm B, Hochhaus G, Rohatagi S, Mollmann H, Barth J, Wagner M, Krieg M, Stockmann R, Derendorf H. 1997. Dependency of cortisol suppression on the administration time of inhaled corticosteroids. J Clin Pharmacol 37(8):704-710.
20. Wu K, Goyal N, Stark JG, Hochhaus G. 2008. Evaluation of the administration time effect on the cumulative cortisol suppression and cumulative lymphocytes suppression for once-daily inhaled corticosteroids: A population modeling/simulation approach. J Clin Pharmacol 48(9):1069-1080.
21. 2003. Guidance for industry: Bioavailability and bioequivalence studies for nasal aerosols and nasal sprays for local action. : U.S. Department of Health and Human Services, Food and Drug Administration.
22. 2000. Guidance for industry: Allergic rhinitis: Clinical development programs for drug products. : U.S. Department of Health and Human Services, Food and Drug Administration.
23. Chrousos GP, Harris AG. 1998. Hypothalamic-pituitary-adrenal axis suppression and inhaled corticosteroid therapy. 2. Review of the literature. Neuroimmunomodulation 5(6):288-308.
24. Robinson JD, Angelini BL, Krahnke JS, Skoner DP. 2002. Inhaled steroids and the risk of adrenal suppression in children. Expert Opin Drug Saf 1(3):237-244.
25. Zollner EW. 2007. Hypothalamic-pituitary-adrenal axis suppression in asthmatic children on inhaled corticosteroids (Part 2)-the risk as determined by gold standard adrenal function tests: A systematic review. Pediatr Allergy Immunol 18(6):469-474.
26. Bruni FM, De Luca G, Venturoli V, Boner AL. 2009. Intranasal corticosteroids and adrenal suppression. Neuroimmunomodulation 16(5):353-362.
27. Chrousos GP, Harris AG. 1998. Hypothalamic-pituitary-adrenal axis suppression and inhaled corticosteroid therapy. 1. General principles. Neuroimmunomodulation 5(6):277-287.
28. Abdu TA, Elhadd TA, Neary R, Clayton RN. 1999. Comparison of the low dose short synacthen test (1 microg), the conventional dose short synacthen test (250 microg), and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease. J Clin Endocrinol Metab 84(3):838-843.
29. Broide J, Soferman R, Kivity S, Golander A, Dickstein G, Spirer Z, Weisman Y. 1995. Low-dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroids. J Clinical Endocrinol Metab 80(4):1243-1246.
30. Tordjman K, Jaffe A, Grazas N, Apter C, Stern N. 1995. The role of the low dose (1 microgram) adrenocorticotropin test in the evaluation of patients with pituitary diseases. J Clin Endocrinol Metab 80(4):1301-1305.
31. Lipworth BJ, Clark DJ, McFarlane LC. 1997. Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children. Thorax 52(8):686-689.
32. Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE. 1997. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 43(2):155-161.
33. Grahnen A, Eckernas SA, Brundin RM, Ling-Andersson A 1994. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol 38(6):521-525.
34. Lonnebo A, Grahnen A, Jansson B, Brundin RM, Ling-Andersson A, Eckernas SA. 1996. An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers. Eur J Clin Pharmacol 49(6):459-463.
35. Dluhy RG. 1998. Clinical relevance of inhaled corticosteroids and HPA axis suppression. J Allergy Clin Immunol 101(4 Pt 2):S447-450.
36. Aaronson D, Kaiser H, Dockhorn R, Findlay S, Korenblat P, Thorsson L, Kallen A. 1998. Effects of budesonide by means of the Turbuhaler on the hypothalmic-pituitary-adrenal axis in asthmatic subjects: A dose-response study. J Allergy Clin Immunol 101(3):312-319.
37. Lipworth BJ, Kaliner MA, LaForce CF, Baker JW, Kaiser HB, Amin D, Kundu S, Williams JE, Engelstaetter R, Banerji DD. 2005. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 94(4):465-472.
38. Sorkness CA, LaForce C, Storms W, Lincourt WR, Edwards L, Rogenes PR. 1999. Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma. Clin Ther 21(2):353-367.
39. Li JT, Goldstein MF, Gross GN, Noonan MJ, Weisberg S, Edwards L, Reed KD, Rogenes PR. 1999. Effects of fluticasone propionate, triamcinolone acetonide, prednisone, and placebo on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol 103(4):622-629.
40. von Berg A, Engelstatter R, Minic P, Sreckovic M, Garcia Garcia ML, Latos T, Vermeulen JH, Leichtl S, Hellbardt S, Bethke TD. 2007. Comparison of the efficacy and safety of ciclesonide 160 microg once daily vs. budesonide 400 microg once daily in children with asthma. Pediatr Allergy Immunol 18(5):391-400.
41. Skoner DP, Maspero J, Banerji D. 2008. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics 121(1):e1-14.
42. Rao R, Gregson RK, Jones AC, Miles EA, Campbell MJ, Warner JO. 1999. Systemic effects of inhaled corticosteroids on growth and bone turnover in childhood asthma: A comparison of fluticasone with beclomethasone. Eur Respir J 13(1):87-94.
43. Toogood JH, Baskerville J, Jennings B, Lefcoe NM, Johansson SA. 1989. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol 84(5 Pt 1):688-700.
44. Toogood JH, Jennings B, Hodsman AB, Baskerville J, Fraher LJ. 1991. Effects of dose and dosing schedule of inhaled budesonide on bone turnover. J Allergy Clin Immunol 88(4):572-580.
45. Price J, Lenney W, Duncan C, Green L, Flood Y, Daley-Yates P, Barnacle H, Efthimiou J. 2002. HPA-axis effects of nebulised fluticasone propionate compared with oral prednisolone in childhood asthma. Respir Med 96(8):625-631.
46. Brannan MD, Herron JM, Reidenberg P, Affrime MB. 1998. A systemic bioactivity comparison of double-strength and regular-strength beclomethasone dipropionate MDI formulations. Ann Allergy Asthma Immunol 80(1):39-44.
47. Brannan MD, Herron JM, Reidenberg P, Affrime MB. 1995. Lack of hypothalamic-pituitary-adrenal axis suppression with once-daily or twice-daily beclomethasone dipropionate aqueous nasal spray administered to patients with allergic rhinitis. Clin Ther 17(4):637-647.
48. Patel D, Ratner P, Clements D, Wu W, Faris M, Philpot E. 2008. Lack of effect on adult and adolescent hypothalamic-pituitary-adrenal axis function with use of fluticasone furoate nasal spray. Ann Allergy Asthma Immunol 100(5):490-496.
49. Vargas R, Dockhorn RJ, Findlay SR, Korenblat PE, Field EA, Kral KM. 1998. Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol 102(2):191-197.
50. Casale TB, Nelson HS, Stricker WE, Raff H, Newman KB. 2001. Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients. Ann Allergy Asthma Immunol 87(5):379-385.
51. Affrime MB, Kosoglou T, Thonoor CM, Flannery BE, Herron JM. 2000. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest 118(6):1538-1546.
52. 1997. Medical review for NDA 020762. Drug at FDA: U.S. Food and Drug Administration.
53. 2006. Medical review for NDA 21247. Accessed on July, 2013, at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021247_aerospan_toc.cfm: U.S. Food and Drug Administration.
54. 2006. Clinical pharmacology and biopharmaceutics review for NDA 021247. Accessed on July, 2013, at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021247s000_ClinPharmR.pdf: U.S. Food and Drug Administration.
55. Meltzer EO, Berger WE, Berkowitz RB, Bronsky EA, Dvorin DJ, Finn AF, Galant SP, Grossman J, Hampel FC, Ratner PH, Ruff ME, Schenkel EJ, Segal AT, Segall N, Stewart GE 2nd, Tripathy I, Skoner DP, Anolik R, Dockhorn RJ, van Bavel J, Mesarina-Wicki B, Nolop K. 1999. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J Allergy Clin Immunol 104(1):107-114.
56. 2000. Medical review for NDA 020911. Accessed on July, 2013, at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-911_Qvar.cfm: U.S. Food and Drug Administration.
57. Hansel TT, Benezet O, Kafe H, Ponitz HH, Cheung D, Engelstatter R, Barnes PJ. 2006. A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma. Clin Ther 28(6):906-920.
58. Synnerstad B, Lindqvist N. 1996. A clinical comparison of intranasal budesonide with beclomethasone dipropionate for perennial non-allergic rhinitis: A 12 month study. Br J Clin Pract 50(7):363-366.
59. Ringdal N, Swinburn P, Backman R, Plaschke P, Sips AP, Kjaersgaard P, Bratten G, Harris TA. 1996. A blinded comparison of fluticasone propionate with budesonide via powder devices in adult patients with moderate-to-severe asthma: A clinical evaluation. Mediators Inflamm 5(5):382-389.
60. 2008. Medical review for NDA 021929. Accessed on July, 2013, at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021929_symbicort_toc.cfm: U.S. Food and Drug Administration.
61. 2007. Clinical pharmacology review for NDA 021658. Accessed on July, 2013, at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021658s000TOC.cfm: U.S. Food and Drug Administration.
62. Skoner DP, Gentile D, Angelini B, Kane R, Birdsall D, Banerji D. 2003. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol 90(1):56-62.
63. 2000. Medical review for NDA 020929. Accessed on July, 2013, at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-929_Pulmicort.cfm: U.S. Food and Drug Administration.
64. Grinspoon SK, Biller BM. 1994. Clinical review 62: Laboratory assessment of adrenal insufficiency. J Clin Endocrinol Metab 79(4):923-931.
65. 2008. Clinical review for NDA 020468. Accessed on July, 2013, at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails: U.S. Food and Drug Administration.
66. Brannan MD, Herron JM, Affrime MB. 1997. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther 19(6):1330-1339.
67. Boulet LP, Cockcroft DW, Toogood J, Lacasse Y, Baskerville J, Hargreave FE. 1998. Comparative assessment of safety and efficacy of inhaled corticosteroids: Report of a committee of the Canadian Thoracic Society. Eur Respir J 11(5):1194-1210.
68. 2005. Medical review for NDA 021067. Accessed on July, 2013, at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021067s000_Asmanex_Twisthaler_MedR.pdf: U.S. Food and Drug Administration.
69. 2007. Clinical pharmacology review for NDA 022124. Accessed on July, 2013, at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022124s000_ClinPharmR.pdf: U.S. Food and Drug Administration.
70. Tripathy I, Levy A, Ratner P, Clements D, Wu W, Philpot E. 2009. HPA axis safety of fluticasone furoate nasal spray once daily in children with perennial allergic rhinitis. Pediatr Allergy Immunol 20(3):287-294.
71. Harrison TW, Wisniewski A, Honour J, Tattersfield AE. 2001. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax 56(3):186-191.
72. 2007. Clinical pharmacology review for NDA 022051. Accessed on July, 2013, at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022051_veramyst_toc.cfm: U.S. Food and Drug Administration.
73. Fardon TC, Lee DK, Haggart K, McFarlane LC, Lipworth BJ. 2004. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med 170(9):960-966.
74. 1999. Clinical pharmacology review for NDA 021077. Accessed on July, 2013, at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21077_Advair%20Diskus_biopharmr.pdf: U.S. Food and Drug Administration.
75. 2006. Clinical pharmacology review for NDA 021254. Accessed on July, 2013, at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021254s000_ClinPharmR.pdf: U.S. Food and Drug Administration.
76. 2010. Clinical pharmacology review for NDA 022518. Accessed on July, 2013, at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022518Orig1s000ClinPharmR.pdf: U.S. Food and Drug Administration.
77. 2006. Medical review for NDA 022124. Accessed on July, 2013, at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022124s000_MedR.pdf: U.S. Food and Drug Administration.
78. 2005. Clinical pharmacology review for NDA 022004. Accessed on July, 2013, at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022004s000_ClinPharmR.pdf: U.S. Food and Drug Administration.
79. Agertoft L, Pedersen S. 2005. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J Allergy Clin Immunol 115(5):940-945.
80. Group FPCPW. 1994. Treatment of seasonal allergic rhinitis with once-daily intranasal fluticasone propionate therapy in children. J Pediatr 125(4):628-634.
81. Knutsson U, Stierna P, Marcus C, Carlstedt-Duke J, Carlstrom K, Bronnegard M. 1995. Effects of intranasal glucocorticoids on endogenous glucocorticoid peripheral and central function. J Endocrinol 144(2):301-310.
82. Chrousos GP, Ghaly L, Shedden A, Iezzoni DG, Harris AG. 2005. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. Chest 128(1):70-77.
83. Skoner DP, Rachelefsky GS, Meltzer EO, Chervinsky P, Morris RM, Seltzer JM, Storms WW, Wood RA. 2000. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 105(2):E23.
84. Wilson AM, McFarlane LC, Lipworth BJ. 1998. Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal axis activity. J Allergy Clin Immunol 101(4 Pt 1):470-474.
85. Lee DK, Robb FM, Sims EJ, Currie GP, McFarlane LC, Lipworth BJ. 2003. Systemic bioactivity of intranasal triamcinolone and mometasone in perennial allergic rhinitis. Br J Clin Pharmacol 55(3):310-313.
86. Fowler SJ, Orr LC, Wilson AM, Sims EJ, Lipworth BJ. 2001. Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate. Br J Clin Pharmacol 52(1):93-95.
87. Donnelly R, Williams KM, Baker AB, Badcock CA, Day RO, Seale JP. 1997. Effects of budesonide and fluticasone on 24-hour plasma cortisol. A dose-response study. Am J Respir Crit Care Med 156(6):1746-1751.
88. Kosoglou T, Cutler DL, Staudinger H, Herron JM. 2010. Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axis. Chest 137(1):115-121.
89. Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A, Rosen JP, Ruff ME, Vandewalker ML, Wanderer A, Damaraju CV, Nolop KB, Mesarina-Wicki B 2000. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 105(2):E22.
90. Skoner DP, Meltzer EO, Milgrom H, Stryszak P, Teper A, Staudinger H. 2011. Effects of inhaled mometasone furoate on growth velocity and adrenal function: A placebo-controlled trial in children 4-9 years old with mild persistent asthma. J Asthma: Official J Assoc Care of Asthma 48(8):848-859.
91. Argenti D, Shah B, Heald D. 2000. A study comparing the clinical pharmacokinetics, pharmacodynamics, and tolerability of triamcinolone acetonide HFA-134a metered-dose inhaler and budesonide dry-powder inhaler following inhalation administration. J Clin Pharmacol 40(5):516-526.
92. McIntyre HD, Mitchell CA, Bowler SD, Armstrong JG, Wooler JA, Cowley DM. 1995. Measuring the systemic effects of inhaled beclomethasone: Timed morning urine collections compared with 24 hour specimens. Thorax 50(12):1280-1284.
93. Hamalainen KM, Malinen A, Granander M, Toivanen P, Silvasti M. 2000. Assessment of the systemic effects of beclomethasone dipropionate inhaled via Easyhaler or via Diskhaler in healthy male volunteers. Eur J Clin Pharmacol 56(9-10):625-629.
94. Goldberg S, Einot T, Algur N, Schwartz S, Greenberg AC, Picard E, Virgilis D, Kerem E. 2002. Adrenal suppression in asthmatic children receiving low-dose inhaled budesonide: Comparison between dry powder inhaler and pressurized metered-dose inhaler attached to a spacer. Ann Allergy Asthma Immunol 89(6):566-571.
95. Girbino G, Lauriello G, Ando F, Cantini L. 1996. Beclomethasone dipropionate given to adult asthmatics through a new spacer device: Effects of high-dose administration. Adv Ther 13(4):220-229.
96. Bosman HG, van Uffelen R, Tamminga JJ, Paanakker LR. 1994. Comparison of inhaled beclomethasone dipropionate 1000 micrograms twice daily and oral prednisone 10 mg once daily in asthmatic patients. Thorax 49(1):37-40.
97. Kim KT, Rabinovitch N, Uryniak T, Simpson B, O'Dowd L, Casty F. 2004. Effect of budesonide aqueous nasal spray on hypothalamic-pituitary-adrenal axis function in children with allergic rhinitis. Ann Allergy Asthma Immunol 93(1):61-67.
98. Bacharier LB, Raissy HH, Wilson L, McWilliams B, Strunk RC, Kelly HW. 2004. Long-term effect of budesonide on hypothalamic-pituitary-adrenal axis function in children with mild to moderate asthma. Pediatrics 113(6):1693-1699.
99. Wilson AM, McFarlane LC, Lipworth BJ. 1998. Effects of low and high doses of inhaled flunisolide and triamcinolone acetonide on basal and dynamic measures of adrenocortical activity in healthy volunteers. J Clin Endocrinol Metab 83(3):922-925.
100. Bachert C, Lukat KF, Lange B. 2004. Effect of intranasal fluticasone propionate and triamcinolone acetonide on basal and dynamic measures of hypothalamic-pituitary-adrenal axis activity in healthy volunteers. Clin Exp Allergy 34(1):85-90.
101. Detsky AS, Sackett DL. 1985. When was a "negative" clinical trial big enough? How many patients you needed depends on what you found. Arch Intern Med 145(4):709-712.
102. Goodman SN, Berlin JA. 1994. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med 121(3):200-206.
103. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. 1996. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 98(6 Pt 1):1051-1057.
104. Chmelik F, Doughty A. 1994. Objective measurements of compliance in asthma treatment. Ann Allergy 73(6):527-532.
105. Kamps AW, Roorda RJ, Brand PL. 2001. Peak flow diaries in childhood asthma are unreliable. Thorax 56(3):180-182.
106. Hyland ME, Kenyon CA, Allen R, Howarth P. 1993. Diary keeping in asthma: Comparison of written and electronic methods. BMJ 306(6876):487-489.
107. Cote J, Cartier A, Malo JL, Rouleau M, Boulet LP. 1998. Compliance with peak expiratory flow monitoring in home management of asthma. Chest 113(4):968-972.